Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals

New Microbiologica

Volumn 27, Issue 1, 2004, Pages 11-15

  Soria, A ^a   Gianotti, N ^a   Cernuschi, M ^a   Lazzarin, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Drug experienced patients; Once daily antiretroviral therapy; Protease inhibitors; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; TREATMENT FAILURE; DRUG COMBINATION; DRUG EFFECT; GENETICS; MIDDLE AGED; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; SELF-SUSTAINED SEQUENCE REPLICATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1842589604     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. ACOSTA, E.P., SAAG, M.S., MONTANER, J.S.G. (2001). Pharmacokinetics and safety of once-daily saquinavir soft gel capsules/ritonavir in HIV-infected antiretroviral naïve patients In: Program and Abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy (Noordwijk, The Netherlands). Utrecht, The Netherlands (Abstract 3.14).: Virology Education BV.
2. BARIL, J.G., TROTTIER, B., LEBLANC, R., LIN, J. (2002). Efficacy of Switching Virologically Suppressed Patients from a Protease Inhibitor (PI) based Therapy to a Saquinavir (SQV) and Low Dose Ritonavir (RTV) Once Daily Dosing Regimen with Therapeutic Drug Monitoring (TDM). In: Program and Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection; 17-21 November 2002; Glasgow, United Kingdom. (Abstract P30).
3. BARIL, J.G., TROTTIER, B., LEBLANC, R., LIN, J. (2002). Efficacy of Once Daily Saquinavir (SQV) and Low Dose Ritonavir (RTV) Containing Salvage Therapy in Heavily Pretreated Patients Who were Not Virologically Suppressed. In: Program and Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection; 17-21 November 2002; Glasgow, United Kingdom. (Abstract P31).
4. CARDIELLO, P.G., VAN HEESWIJK, R.P., HASSINK, E.A., SRASUEBKUL, P., MAHANONTHARIT, A., SAMOR, T.M., WORARIEN, W., BEIJNEN, J.H., HOETELMANS, R.M., RUXRUNGTHAM, K., COOPER, D.A., LANGE, J.M., PHANUPHAK, P. (2002). Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. Journal of Acquired Immune Deficiency Syndrome. 29: 464-70.
5. CARDIELLO, P.G., MONHAPHOL, T., MAHANONTHARIT, A., VAN HEESWIJK, R.P., BURGER, D., HILL, A., RUXRUNGTHAM, K., LANGE, J.M., COOPER, D.A., PHANUPHAK, P. (2003). Pharmacokinetics of Once-Daily Saquinavir Hard-Gelatin Capsules and Saquinavir Soft-Gelatin Capsules Boosted With Ritonavir in HIV-1-Infected Subjects. Journal of Acquired Immune Deficiency Syndrome. 32: 375-379.
6. EISEN, S.A., MILLER, D.K., WOODWARD, R.S., SPINAGEL, E., PRZYBECK, T.R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine. 150: 1881-1884.
7. FIGGIT, D.P., PLOSKER, G.L. (2000). Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs. 60: 481-516.
8. HAUBRICH, R.H., LITTLE, S.J., CURRIER, J.S., FORTHAL, D.N., KEMPER, C.A., BEALL, G.N., JOHNSON, D., DUBE, M.P., HWANG, J.Y., MCCUTCHAN, J.A. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 13: 1099-1107.
9. HOETELMANS, R.M.W., VAN HEESWIJK, R.P., MEENHORST, P.L. (1998). Plasma concentrations of saquinavir (SQV) determine HIV-1 response over a 48-week period. In: Conference Record of the 12th World AIDS Conference (Geneva) (Abstract 42261). Geneva: Marathon Multimedia.
10. KILBY, J.M., SFAKIANOS, G., GIZZI, N., SIEMON-HRYCZYK, P., EHRENSING, E., OO, C., BUSS, N., SAAG, M.S. (2000). Safety and pharmacokinetics of once-daily regimens of soft gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrobial Agents and Chemotherapy. 44: 2672-2678.
11. MONTANER, J.S.G., SAAG, M., SCHWARTZ, R. (2000). Pharmacokinetic and Safety Evaluations of a Once Daily Regimen of Saquinavir Soft Gel Capsules (SQV) in HIV-infected Anti Retroviral Naive Patients. Presented at: Frontiers in Drug Development for Antiretroviral Therapies (DART); December 18, 2000, Puerto Rico. (Abstract 048).
12. MONTANER, J., SAAG, M.S., BARYLSKI, C., SIEMONHRYCZYK, P. (2002). FOCUS study: saquinavir QD regimen versus Efavirenz QD regimen 48 week analysis in HIV infected patients. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology. (Abstract H-167).
13. MOYLE, G. (1998). The role of combination of HIV protease inhibitors in the management of persons with HIV infection. Expert Opinion on Investigational Drugs. 7: A13-A26.
14. PATERSON, D.L., SWINDELLS, S., MOHR, J., BRESTER, M., VERGIS, E.N., SQUIER, C., WAGENER, M.M., SINGH, N. (2000). Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Annals of Internal Medicine. 133: 21-30.
15. VAN HEESWIJK, R.P., COHEN STUART, J.W., BURGER, D.M., BEIJNEN, J.H., BORLEFFS, J.C., HOETELMANS, R.M. (2002). Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. British Journal of Clinical Pharmacology. 53: 211-212.
16. VAN HEESWIJK, R.P.G., VELDKAMP, A.I., MULDER, J.W., MEENHORST, P.L., LANGE, J.M.A., BEIJNEN, J.H., HOETELMANS, R.M.W. (2000). Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. AIDS. 14: F103-F110.
17. VELDKAMP, A.I., VAN HEESWIJK, R.P., MULDER, J.W., MEENHORST, P.L., SCHREIJ, G., VAN DER GEEST, S., LANGE, J.M., BEIJNEN, J.H., HOETELMANS, R.M. (2001). Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndrome. 27: 344-349.
18. WRIGHT, D., PITHEY, C. (2000). Virologic Improvement in Patients Receiving Once-daily Saquinavir/Mini-dose Ritonavir (SQV/r) Therapy in Clinical Practice. Presented at: 38th Annual Meeting of IDSA, Sept. 2000. (Paper 200230).